ArticleFrontiers in virology (Lausanne, Switzerland)2022
APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants.
Richa Dwivedi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.